UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
Current Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 22, 2019
 
DARÉ BIOSCIENCE, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
 
001-36395
 
20-4139823
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(I.R.S. Employer
Identification No.)
 
3655 Nobel Drive, Suite 260
San Diego, CA 92122
(Address of Principal Executive Offices and Zip Code)
Registrant’s telephone number, including area code: (858) 926-7655
 
Not Applicable
(Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
   
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company   x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   x





Item 8.01
Other Events
The 2019 annual meeting of stockholders (the “2019 annual meeting”) of Daré Bioscience, Inc. (the “Company”), will be held on June 13, 2019. Under the Company’s by-laws, because the date of the 2019 annual meeting is advanced by more than 20 days from the first anniversary of the 2018 annual meeting of stockholders, to be timely, any written notice from a stockholder interested in bringing business before, or nominating a director candidate for election at, the 2019 annual meeting must be received in writing by the Company’s Secretary at the Company’s principal executive offices not later than the close of business on May 2, 2019. Any such notice must comply with the applicable advance notice provisions of the Company's by-laws and any stockholder proposal intended to be considered for inclusion in the Company's proxy materials for the 2019 annual meeting must comply with all applicable rules and regulations promulgated by the Securities and Exchange Commission under the Securities Exchange Act of 1934.







SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
DARÉ BIOSCIENCE, INC.
 
Date: April 22, 2019
 
 
By:
 
/s/ Sabrina Martucci Johnson
 
 
 
Name:
 
Sabrina Martucci Johnson
 
 
 
Title:
 
Chief Executive Officer


Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Dare Bioscience Charts.
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Dare Bioscience Charts.